SHIRLEY, NY, May 20, 2026 /24-7PressRelease/ — By integrating high-sensitivity ctDNA sequencing and advanced methylation analysis, the company is addressing the critical need for noninvasive monitoring and early-stage cancer detection in the burgeoning field of precision oncology.
Bridging the Gap in Cancer Diagnostics
Traditional tissue biopsies, while informative, often face limitations due to invasiveness and the inability to capture the full spatial-temporal heterogeneity of tumors. Creative Biolabs’ latest suite of ctDNA sequencing services offers a transformative alternative. By isolating and analyzing circulating tumor DNA (ctDNA) from peripheral blood, researchers can now track tumor dynamics in real-time, evaluate treatment response, and detect minimal residual disease (MRD) with unprecedented accuracy.
“The shift toward liquid biopsy represents a paradigm change in how we understand cancer progression,” stated a senior scientist at Creative Biolabs. “By leveraging our ultra-deep sequencing technology, we can identify low-frequency mutations that were previously beneath the detection threshold, providing a clearer window into the molecular landscape of the disease.”
Deciphering the Epigenetic Code: ctDNA Methylation
Recognizing that genetic mutations are only one piece of the diagnostic puzzle, Creative Biolabs has fortified its platform with specialized ctDNA methylation sequencing. This technology examines epigenetic modifications, which often occur earlier than genetic mutations in many cancer types. This dual-omics approach—combining genetic and epigenetic data—significantly enhances the sensitivity of early screening and helps in pinpointing the tissue of origin (TOO) for unknown primary tumors.
Technical Insights: How Liquid Biopsy Transforms Research
To assist researchers in navigating these complex technologies, Creative Biolabs provides comprehensive technical support. Common inquiries from the field often center on the practicalities of implementation:
Detection Sensitivity: The SuPrecision™ platform utilizes advanced molecular barcoding to distinguish true somatic mutations from sequencing artifacts, ensuring high specificity even at a 0.1% variant allele frequency (VAF).
Clinical Utility: Beyond initial diagnosis, these services are pivotal for longitudinal monitoring, allowing for the detection of “escape mutations” that may signal the onset of drug resistance before radiological evidence appears.
Explore the future of oncology research today. Researchers interested in advancing their liquid biopsy projects are encouraged to consult with the SuPrecision™ technical team for a tailored project evaluation.
About Creative Biolabs
Creative Biolabs is a premier provider of customized biotechnology solutions, supporting drug discovery and medical research worldwide. Its SuPrecision™ platform is dedicated to providing high-throughput sequencing services that empower scientists to decode the complexities of the human genome and develop the next generation of targeted therapies.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: The content on this page is syndicated from independent third-party providers. Kyrion Media makes no warranties or representations regarding the accuracy, completeness, legality, or reliability of the information, including text, images, videos, or licenses. If you are affiliated with this content or have any complaints, copyright concerns, or requests for removal, please contact us at retract@kyrionmedia.com with the specific URL of the content in question. We will review and address valid requests promptly.
